MAGAZINE

Investigative Ophthalmology & Visual Science

Point-of-care Diabetic Retinopathy screening with a low-cost portable retinal camera, artificial intelligence and staged mydriasis in a rural, underserved area

AUTHORS & DATE

Fernando Korn Malerbi; Viviane Cardoso; Lucas Andrade Santos; Gustavo Barreto Melo
21/06/2023

Abstract

Background

The use of mydriasis may discourage attendance at diabetic retinopathy (DR) screening initiatives. However, low gradeability decreases the efficiency of non- mydriatic programs. We performed a retrospective, observational clinical study to assess the gradeability of retinal imaging obtained with a non-mydriatic handheld retinal camera.

Methods

We included 968 persons with diabetes (PWD) followed at the primary care level from a rural, semiarid setting in Northeast Brazil; 65.9% were women. Mean (± SD) age and diabetes duration were 60.3 ± 14.2 years of age and 8.0 ± 7.2 years, respectively. A trained technician obtained ocular images in darkened rooms initially without pupil dilation and then evaluated image quality. Referable DR, defined as nonproliferative severe or proliferative DR or the presence of diabetic maculopathy, was detected automatically by a previously validated artificial intelligence (AI) system, embedded in the device. Patients with inadequate images underwent pupil dilation and then new evaluation; those with ungradable images even after mydriasis, along with cases of referable DR, were sent for ophthalmological evaluation. Exclusion criteria were corneal opacities that precluded DR classification. The main outcome measure was image gradeability. Statistical analysis included Mann-Whitney test, chi-square test and t-test.

Results

Of 986 PWD, 64.2% had systemic hypertension; 17.7% used insulin; 28.5% had undergone fundus examination in the past; 20.6% were illiterate and 50.6% had only elementary education level; only 3.4% had health insurance. Gradeability was possible for 858 individuals (88.6%), 85 of whom (9.9%) presenting with referable DR; ungradeability was associated with older age (p=0.000) and longer diabetes duration (p=0.000). Among patients with gradable images, 81% did not require pupil dilation; need for pharmacological mydriasis was associated with older age (p=0.000), longer diabetes duration (p=0.000), higher rates of hypertension (p=0.002) and more severe DR (p=0.000).

Conclusion

A staged mydriasis strategy with a low-cost portable camera and AI attained a gradeability rate of almost 90% in a real-world, low-resource setting; pupil dilation was not required for 81% of patients with gradable images. Avoiding unnecessary pupil dilation contributes to increased adherence of DR screening programs.

Icon Button Request A QuoteRequest a Quote

Fechar

Ico Back

Later

Request a quote

Fill out the form below and we will contact you shortly.

    Ico Form Success

    Request a Quote

    Our team will contact you shortly.

    Close

    …complete suas informações

      By clicking the Complete button I allow Phelcom to contact me regarding the above request and I declare that I have read and accept the terms of Privacy Policy and Terms of Use.
      Ico Back

      Depois

      Ico Form Success

      Obrigado por completar suas informações

      FECHAR

      Ico Back

      Depois

      Solicite e comece SEU TEST DRIVE

      Por favor, preencha o formulário abaixo que entraremos em contato.

        x

        Solicitar Orçamento

        Ao clicar em Solicitar, concordo com a Política de Privacidade e os Termos de Uso, permito que a Phelcom me contate e reconheço que o Eyer é um dispositivo médico (Anvisa classe II) exigindo a supervisão de um profissional com CRM para uso e interpretação das imagens.
        Ico Form Success

        Obrigado!

        Nosso time comercial logo entrará em contato para finalizar o processo.

        FECHAR

        Ico Back

        Later

        Request more information

        Please fill out the form below and we will contact you.

          x

          Request EyerMaps

          By clicking the Request button I allow Phelcom to contact me regarding the above request and I declare that I have read and accept the terms of Privacy Policy and Terms of Use.
          Ico Form Success

          Thank you!

          Our commercial team will contact you shortly to finalize the process.Our commercial team will contact you shortly to finalize the process.
          CLOSE